Raffaghello L et al., 2010-11-15: Commentary by the Longo laboratory summarising its own 10-patient case series of fasting with chemotherapy, reporting reduced side effects and 'possibly augmented' efficacy.
In a recent article, 10 patients who fasted in combination with chemotherapy, reported that fasting was not only feasible and safe but caused a reduction in a wide range of side effects accompanied by an apparently normal and possibly augmented chemotherapy efficacy.
Abstract
Raffaghello L et al., 2010-11-15: Commentary by the Longo laboratory summarising its own 10-patient case series of fasting with chemotherapy, reporting reduced side effects and 'possibly augmented' efficacy. Uncontrolled, retrospective, patient-selected; the authors call the human data 'preliminary'. Funders not stated in the record. This is the origin document for the book's fasting claim and is much weaker than the DIRECT trial (CHG-27).
